# Amitabh Chandra

Top podcast episodes
Updated:

Data analysis and policy design—not good intentions—will fix healthcare post COVID

As healthcare policy navigates what is widely seen as a historic inflection point, Harvard Kennedy School professors Amitabh Chandra and Soroush Saghafian say policymakers need to pursue change with care, deeply analyzing the weaknesses the COVID-19 pandemic exposed and using that data to design in…

IRA's Impact on Biopharma Innovation with Amitabh Chandra

With the US Inflation Reduction Act now law, many in Washington DC are saying that it’s provisions reducing pricing by $80 billion dollars annually in Medicare for drugs near the end of their patent life will not have any negative impacts on the US biopharma ecosystem.  Enter Amitabh Chandra, the …

Ep. 64: Reconceptualizing the path to universal health insurance

For decades US policymakers have tried to achieve the universal health insurance coverage that many other developed countries enjoy. But despite incremental reforms, based on tweaking health insurance markets, America's uninsured population has remained stubbornly high. In a paper in the Journal o…

Ep. 65: Economic questions raised by Alzheimer's disease

The costs of Alzheimer's disease are significant. In 2021, it affected nearly 6 million Americans and accounted for an estimated 8 percent of total US health-care spending—about as much as cancer and heart disease combined. And those numbers are only expected to increase as the population ages. In…

Amitabh Chandra - IRA’s potential impact on the US biopharma ecosystem

Amitabh Chandra is the director of health policy research at the Harvard Kennedy School of Government, and a professor of business administration at Harvard Business School. Dr Chandra is a rare voice sounding an alarm about the unintended consequences of the drug pricing provisions of the inflatio…

Rebooting American Health Care, with Amy Finkelstein

How can public policy improve upon and fix the mess of U.S. health care? In a new book, health economists Amy Finkelstein (MIT) and Liran Einav (Stanford) argue that's the wrong question. Instead, they suggest we ask: What is it that U.S. health policy should try to accomplish? Finkelstein, also a …

Is It Time to Regulate Prices in Health Care?

Howdy folks - Welcome to the first episode of 584 Vetoes, a new podcast I’m doing with Danny Heil. This week we’re discussing why price controls and “using the government’s size to drive down prices” aren’t the simple solutions in health care that they appear to be. It’s our first episode, so we’d…

Episode 20: Amitabh Chandra and the productivity of scientists

We had the pleasure to record an episode with Amitabh Chandra. We discuss his working paper "Productivity Differences in Fundamental Life-Sciences Discovery" co-authored with Connie Xu. The aim of the paper is to research whether a life scientist's university has an effect on their productivity. To…

NEJM Interview: Amitabh Chandra on why corporatization occurs in health care, when it can succeed, and why it can go wrong.

Amitabh Chandra is a professor of public policy at the Harvard Kennedy School of Government and a professor of business administration at Harvard Business School. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. A. Chandra and M. Shepard. The Corporatization Deal…